Pinaka™ is a blood-based biomarker profiling test designed to evaluate clinically relevant cancer biomarkers directly on circulating tumor cells (CTCs). Using immunocytochemistry (ICC), it assesses key therapeutic markers including PD-L1, ER, PR, and HER2—providing biomarker status aligned with established clinical guidelines. By analyzing tumor-derived cells in circulation, Pinaka offers real-time biomarker status without the need for invasive tissue biopsies. This supports clinical decision-making when interpreted alongside standard guidelines, particularly in cases where tissue is unavailable, insufficient, or may not reflect current tumor biology.
Enabling Biomarker-Based Clinical Evaluation
Assess therapeutic biomarkers through a simple blood draw without requiring tumor tissue
Can be performed without the need for specialized biopsy procedures or hospitalization
Reflects current tumor biology rather than historical tissue samples
Biomarker status interpreted in line with NCCN / ESMO / NICE frameworks
CTC-Based ICC for Real-Time Tumor Biology
Direct evaluation of circulating tumor cells representing active disease
Biomarker expression on CTCs has shown correlation with tumor tissue in multiple settings
PD-L1, ER, PR, and HER2 evaluated using validated ICC methods
Useful when biopsy is not feasible, insufficient, or non-representative
Biomarker Insights for Clinical Context
Identifies presence or absence of clinically relevant biomarkers
Provides biomarker information to support therapy considerations alongside clinical guidelines
Offers biomarker insights in evolving or previously treated disease settings
Provides biomarker data when tumor samples are unavailable or insufficient
Biomarker results presented using defined clinical thresholds
Clinically Relevant ICC-Based Markers
Therapeutic decisions in oncology often depend on biomarker status derived from tumor tissue. However, tissue biopsies can be invasive, limited, or may not fully capture tumor heterogeneity. Pinaka™ enables non-invasive evaluation of key biomarkers on circulating tumor cells, offering a practical and real-time alternative. This approach helps overcome sampling limitations and supports timely clinical evaluation and decision-making.
Peripheral blood sample collected in a routine clinical setting
Isolation of circulating tumor cells from the blood sample
Evaluation of PD-L1, ER, PR, and HER2 expression on CTCs
Assessment of positivity/negativity aligned with defined clinical thresholds
Structured report presenting CTC detection and biomarker status (positive/negative) for clinical interpretation